Metformin exerts anti-obesity effect via gut microbiome modulation in prediabetics: A hypothesis

Medical Hypotheses

Volumn 104, Issue , 2017, Pages 117-120

  Maniar, Kunal ^a   Moideen, Amal ^a   Bhattacharyya, Rajasri ^a   Banerjee, Dibyajyoti ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Butyrate producing taxa; Insulin; Metformin; Microbiome; Obesity; Prediabetes

Indexed keywords

BUTYRIC ACID; GLUCOSE; INSULIN; METFORMIN; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; BUTYRIC ACID DERIVATIVE; HORMONE;

ANTIOBESITY ACTIVITY; ARTICLE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DYSBIOSIS; HUMAN; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; INTESTINE FLORA; NONHUMAN; ANIMAL; BLOOD; CHEMISTRY; COMPLICATION; DRUG EFFECTS; INFLAMMATION; INSULIN RESISTANCE; METABOLISM; MICROFLORA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; THEORETICAL MODEL;

ANIMALS; ANTI-OBESITY AGENTS; BUTYRATES; DIABETES MELLITUS, TYPE 2; GASTROINTESTINAL MICROBIOME; HORMONES; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; METFORMIN; MICROBIOTA; MODELS, THEORETICAL; OBESITY; PREDIABETIC STATE;

EID: 85020279172     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2017.06.001     Document Type: Article

References (57)

1. James, W.P.T., WHO recognition of the global obesity epidemic. Int J Obes 2008:32 Suppl 7 (2005), S120–S126, 10.1038/ijo.2008.247.
2. Hurt, R.T., Kulisek, C., Buchanan, L.A., McClave, S.A., The obesity epidemic: challenges, health initiatives, and implications for gastroenterologists. Gastroenterol Hepatol 6 (2010), 780–792.
3. Must, A., McKeown, N.M., The Disease Burden Associated with Overweight and Obesity. De Groot, L.J., Chrousos, G., Dungan, K., Feingold, K.R., Grossman, A., Hershman, J.M., et al. (eds.) Endotext, 2000, MDText.com, Inc., South Dartmouth (MA).
4. Pradeepa, R., Anjana, R.M., Joshi, S.R., Bhansali, A., Deepa, M., Joshi, P.P., et al. Prevalence of generalized & abdominal obesity in urban & rural India–the ICMR-INDIAB Study (Phase-I) [ICMR- NDIAB-3]. Indian J Med Res 142 (2015), 139–150, 10.4103/0971-5916.164234.
5. Mi, Y.-J., Zhang, B., Wang, H.-J., Yan, J., Han, W., Zhao, J., et al. Prevalence and secular trends in obesity among chinese adults, 1991–2011. Am J Prev Med 49 (2015), 661–669, 10.1016/j.amepre.2015.05.005.
6. Hammond, R.A., Levine, R., The economic impact of obesity in the United States. Diabetes Metab Syndr Obes Targets Ther 3 (2010), 285–295, 10.2147/DMSOTT.S7384.
7. Yang, Z., Hall, A.G., The financial burden of overweight and obesity among elderly Americans: the dynamics of weight, longevity, and health care cost. Health Serv Res 43 (2008), 849–868, 10.1111/j.1475-6773.2007.00801.x.
8. Bansal, N., Prediabetes diagnosis and treatment: a review. World J Diabetes 6 (2015), 296–303, 10.4239/wjd.v6.i2.296.
9. Rhee, S.Y., Woo, J.-T., The prediabetic period: review of clinical aspects. Diabetes Metab J, 35, 2011, 107, 10.4093/dmj.2011.35.2.107.
10. Kaur, J., A comprehensive review on metabolic syndrome. Cardiol Res Pract, 2014, 2014, 943162, 10.1155/2014/943162.
11. Leblanc, E.S., O'Connor, E., Whitlock, E.P., Patnode, C.D., Kapka, T., Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 155 (2011), 434–447, 10.7326/0003-4819-155-7-201110040-00006.
12. Wing, R.R., Tate, D.F., Gorin, A.A., Raynor, H.A., Fava, J.L., A self-regulation program for maintenance of weight loss. N Engl J Med 355 (2006), 1563–1571, 10.1056/NEJMoa061883.
13. Goitein, D., Raziel, A., Szold, A., Sakran, N., Assessment of perioperative complications following primary bariatric surgery according to the Clavien-Dindo classification: comparison of sleeve gastrectomy and Roux-Y gastric bypass. Surg Endosc 30 (2016), 273–278, 10.1007/s00464-015-4205-y.
14. Rodgers, R.J., Tschöp, M.H., Wilding, J.P.H., Anti-obesity drugs: past, present and future. Dis Model Mech 5 (2012), 621–626, 10.1242/dmm.009621.
15. Shen, J., Obin, M.S., Zhao, L., The gut microbiota, obesity and insulin resistance. Mol Aspects Med 34 (2013), 39–58, 10.1016/j.mam.2012.11.001.
16. Duca, F.A., Côté, C.D., Rasmussen, B.A., Zadeh-Tahmasebi, M., Rutter, G.A., Filippi, B.M., et al. Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. Nat Med 21 (2015), 506–511, 10.1038/nm.3787.
17. McCreight, L.J., Bailey, C.J., Pearson, E.R., Metformin and the gastrointestinal tract. Diabetologia 59 (2016), 426–435, 10.1007/s00125-015-3844-9.
18. Lambeth, S.M., Carson, T., Lowe, J., Ramaraj, T., Leff, J.W., Luo, L., et al. Composition, diversity and abundance of gut microbiome in prediabetes and type 2 diabetes. J Diabetes Obes 2 (2015), 1–7, 10.15436/2376-0949.15.031.
19. Ley, R.E., Bäckhed, F., Turnbaugh, P., Lozupone, C.A., Knight, R.D., Gordon, J.I., Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 102 (2005), 11070–11075, 10.1073/pnas.0504978102.
20. Lloyd-Price, J., Abu-Ali, G., Huttenhower, C., The healthy human microbiome. Genome Med, 8, 2016, 51, 10.1186/s13073-016-0307-y.
21. Santacruz, A., Collado, M.C., García-Valdés, L., Segura, M.T., Martín-Lagos, J.A., Anjos, T., et al. Gut microbiota composition is associated with body weight, weight gain and biochemical parameters in pregnant women. Br J Nutr 104 (2010), 83–92, 10.1017/S0007114510000176.
22. Collado, M.C., Isolauri, E., Laitinen, K., Salminen, S., Distinct composition of gut microbiota during pregnancy in overweight and normal-weight women. Am J Clin Nutr 88 (2008), 894–899.
23. Gao, X., Jia, R., Xie, L., Kuang, L., Feng, L., Wan, C., Obesity in school-aged children and its correlation with gut E. coli and Bifidobacteria: a case-control study. BMC Pediatr, 15, 2015, 64, 10.1186/s12887-015-0384-x.
24. Louis, S., Tappu, R.-M., Damms-Machado, A., Huson, D.H., Bischoff, S.C., Characterization of the gut microbial community of obese patients following a weight-loss intervention using whole metagenome shotgun sequencing. PLoS One, 11, 2016, e0149564, 10.1371/journal.pone.0149564.
25. Dimitriadis, G., Mitrou, P., Lambadiari, V., Maratou, E., Raptis, S.A., Insulin effects in muscle and adipose tissue. Diabetes Res Clin Pract 93:Suppl 1 (2011), S52–S59, 10.1016/S0168-8227(11)70014-6.
26. Lo, K.A., Labadorf, A., Kennedy, N.J., Han, M.S., Yap, Y.S., Matthews, B., et al. Analysis of in vitro insulin-resistance models and their physiological relevance to in vivo diet-induced adipose insulin resistance. Cell Rep 5 (2013), 259–270, 10.1016/j.celrep.2013.08.039.
27. Plotkin, B.J., Viselli, S.M., Effect of insulin on microbial growth. Curr Microbiol 41 (2000), 60–64.
28. Chakraborty, S., Mittal, A., Banerjee, D., Human recombinant insulin in supraphysiological concentration support bacterial growth in glucose independent manner. Int J Drug Dev Res 8 (2016), 35–40.
29. Vrieze, A., Van Nood, E., Holleman, F., Salojärvi, J., Kootte, R.S., Bartelsman, J.F.W.M., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology, 143(913–916), 2012, e7, 10.1053/j.gastro.2012.06.031.
30. Blackard, W.G., Nelson, N.C., Portal and peripheral vein immunoreactive insulin concentrations before and after glucose infusion. Diabetes 19 (1970), 302–306.
31. Blackard, W.G., Nelson, N.C., Portal vein insulin concentrations in diabetic subjects. Diabetes 20 (1971), 286–288.
32. Kim, A., Dysbiosis: a review highlighting obesity and inflammatory bowel disease. J Clin Gastroenterol 49:Suppl 1 (2015), S20–S24, 10.1097/MCG.0000000000000356.
33. Zhang, X., Shen, D., Fang, Z., Jie, Z., Qiu, X., Zhang, C., et al. Human gut microbiota changes reveal the progression of glucose intolerance. PLoS One, 8, 2013, e71108, 10.1371/journal.pone.0071108.
34. Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., Magrini, V., Mardis, E.R., Gordon, J.I., An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444 (2006), 1027–1031, 10.1038/nature05414.
35. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet Lond Engl 352 (1998), 854–865.
36. Gokcel, A., Gumurdulu, Y., Karakose, H., Melek Ertorer, E., Tanaci, N., BascilTutuncu, N., et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 4 (2002), 49–55.
37. Glueck, C.J., Fontaine, R.N., Wang, P., Subbiah, M.T., Weber, K., Illig, E., et al. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism 50 (2001), 856–861, 10.1053/meta.2001.24192.
38. The diabetes prevention program: baseline characteristics of the randomized cohort. The diabetes prevention program research group. Diabetes Care 23 (2000), 1619–1629.
39. Kendall, D., Vail, A., Amin, R., Barrett, T., Dimitri, P., Ivison, F., et al. Metformin in obese children and adolescents: the MOCA trial. J Clin Endocrinol Metab 98 (2013), 322–329, 10.1210/jc.2012-2710.
40. Buse, J.B., DeFronzo, R.A., Rosenstock, J., Kim, T., Burns, C., Skare, S., et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-Week dose-ranging studies. Diabetes Care 39 (2016), 198–205, 10.2337/dc15-0488.
41. Rotroff, D.M., Oki, N.O., Liang, X., Yee, S.W., Stocker, S.L., Corum, D.G., et al. Pharmacometabolomic assessment of metformin in non-diabetic. African Americans. Front Pharmacol, 7, 2016, 135, 10.3389/fphar.2016.00135.
42. Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528 (2015), 262–266, 10.1038/nature15766.
43. de la Cuesta-Zuluaga, J., Mueller, N.T., Corrales-Agudelo, V., Velásquez-Mejía, E.P., Carmona, J.A., Abad, J.M., et al. Metformin is associated with higher relative abundance of mucin-degrading akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut. Diabetes Care 40 (2017), 54–62, 10.2337/dc16-1324.
44. Zhang, X., Zhao, Y., Xu, J., Xue, Z., Zhang, M., Pang, X., et al. Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. Sci Rep, 5, 2015, 14405, 10.1038/srep14405.
45. Cabreiro, F., Au, C., Leung, K.-Y., Vergara-Irigaray, N., Cochemé, H.M., Noori, T., et al. Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell 153 (2013), 228–239, 10.1016/j.cell.2013.02.035.
46. Lee, H., Ko, G., Effect of metformin on metabolic improvement and gut microbiota. Appl Environ Microbiol 80 (2014), 5935–5943, 10.1128/AEM.01357-14.
47. Lopetuso, L.R., Scaldaferri, F., Petito, V., Gasbarrini, A., Commensal Clostridia: leading players in the maintenance of gut homeostasis. Gut Pathog, 5, 2013, 23, 10.1186/1757-4749-5-23.
48. Gao, Z., Yin, J., Zhang, J., Ward, R.E., Martin, R.J., Lefevre, M., et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 58 (2009), 1509–1517, 10.2337/db08-1637.
49. Eppinga, R.N., Hartman, M.H.T., van Veldhuisen, D.J., Lexis, C.P.H., Connelly, M.A., Lipsic, E., et al. Effect of metformin treatment on lipoprotein subfractions in non-diabetic patients with acute myocardial infarction: a glycometabolic intervention as adjunct to primary coronary intervention in ST elevation myocardial infarction (GIPS-III) trial. PLoS One, 11, 2016, e0145719, 10.1371/journal.pone.0145719.
50. Glucose lowering in non-diabetic hyperglycaemia trial : Overview n.d. https://www.dtu.ox.ac.uk/GLINT/ (accessed November 11, 2016).
51. Sussman, J.B., Kent, D.M., Nelson, J.P., Hayward, R.A., Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program. BMJ, 350, 2015, h454.
52. Pastor-Villaescusa, B., Caballero-Villarraso, J., Cañete, M.D., Hoyos, R., Maldonado, J., Bueno, G., et al. Evaluation of differential effects of metformin treatment in obese children according to pubertal stage and genetic variations: study protocol for a randomized controlled trial. Trials, 17, 2016, 323, 10.1186/s13063-016-1403-4.
53. Levri, K.M., Slaymaker, E., Last, A., Yeh, J., Ference, J., D'Amico, F., et al. Metformin as treatment for overweight and obese adults: a systematic review. Ann Fam Med 3 (2005), 457–461, 10.1370/afm.343.
54. Gagnon, J., Sheppard, E., Anini, Y., Metformin directly inhibits ghrelin secretion through AMP-activated protein kinase in rat primary gastric cells. Diabetes Obes Metab 15 (2013), 276–279, 10.1111/dom.12021.
55. Mulherin, A.J., Oh, A.H., Kim, H., Grieco, A., Lauffer, L.M., Brubaker, P.L., Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology 152 (2011), 4610–4619, 10.1210/en.2011-1485.
56. Lee, A., Morley, J.E., Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res 6 (1998), 47–53.
57. Bailey, C.J., Turner, R.C., Metformin. N Engl J Med 334 (1996), 574–579, 10.1056/NEJM199602293340906.